 NEW YORK, Sept. 8, 2021 PRNewswire -- Today, Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema. 